Trial · NCT06561022
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
NCT06561022, Phase 2, Unknown, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping. Trials, record NCT06561022. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06561022
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- NCT number
- NCT06561022
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 260 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Breast Cancer
- Interventions
- Fluzoparib, Everolimus, Fulvestrant, Abemaciclib
- First posted
- 2024-08-19
- Last updated
- 2024-08-19
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Primary | objective response rate (ORR)( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | objective response rate (ORR) |
| Primary | Progression-free survival (PFS)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Progression-free survival (PFS) |
| Secondary | Overall survival (OS)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Overall survival (OS) |
| Secondary | objective response rate (ORR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | objective response rate (ORR) |
| Secondary | clinical benefit rate (CBR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | clinical benefit rate (CBR) |
| Secondary | duration of response (DOR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | duration of response (DOR) |
| Secondary | time to first response (TTR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | time to first response (TTR) |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Secondary | Clinical benefit rate (CBR)( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Clinical benefit rate (CBR) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06561022
GET https://conductscience.org/api/trials/v1/NCT06561022/registered